Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BOM:539206's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.9 * Ranked among companies with meaningful Gross Margin % only.
Genomic Valley Biotech had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Genomic Valley Biotech was 0.00% per year.
Genomic Valley Biotech (BOM:539206) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Genomic Valley Biotech had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Genomic Valley Biotech Gross Margin % Related Terms
Genomic Valley Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Genomic Valley Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:539206 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, Genomic Valley Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomic Valley Biotech Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomic Valley Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Genomic Valley Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Genomic Valley Biotech (BOM:539206) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Genomic Valley Biotech and its competitors. Over the past decade, Genomic Valley Biotech's Gross Margin % has ranged from 41.83 to 107.73. According to the industry distribution chart, Genomic Valley Biotech ranks #999999 out of 735 companies in the Biotechnology industry.
Is Genomic Valley Biotech's Gross Margin % too high?
Genomic Valley Biotech's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 41.83 to a high of 107.73. Based on the distribution chart, Genomic Valley Biotech ranks #999999 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genomic Valley Biotech has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomic Valley Biotech ranks #999999 out of 735 companies for Gross Margin %. This places Genomic Valley Biotech in the lower half of its industry. The industry median Gross Margin % is 60.90. Historically, Genomic Valley Biotech's own Gross Margin % has ranged from 41.83 to 107.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Genomic Valley Biotech and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomic Valley Biotech's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹12.92, compared to a current price of ₹29.29 — trading 126.7% above its estimated fair value. The current Gross Margin % is 0.00%. Genomic Valley Biotech's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?
Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued.
The current stock price of ₹29.29 is trading 126.7% above its estimated GF Value™ of ₹12.92.
GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.
Key valuation signals for BOM:539206:
Gross Margin %: 0.00%
GF Value™: ₹12.92 vs. price of ₹29.29 (126.7% above fair value)
No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
57GF Score
Get the complete analysis for BOM:539206
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539206 has been successfully added to your 
